GRI
GRI Bio, Inc. (NASDAQ)
Healthcare — Biotechnology
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Price History
Fundamentals
| Market Cap | $3.15M |
| P/E Ratio (TTM) | 0.05 |
| Forward P/E | -0.70 |
| EPS (TTM) | $38.89 |
| Dividend Yield | - |
| Profit Margin | - |
| Revenue Growth | - |
| ROE | -185.67% |
| Debt/Equity | 0.55 |
| Recommendation | None |
| Analyst Target | $21.00 |
| Analysts | 2 |
| Indexes | NASDAQ |
Technical Indicators
| RSI (14) | 28.8 |
| Beta | -0.66 |
| SMA 20 | - |
| SMA 40 | - |
| 52-Week High | $80.36 |
| 52-Week Low | $1.70 |
| 50-Day Avg | $2.15 |
| 200-Day Avg | $18.91 |
| Avg Volume | 65.6K |
| Volume | 23.1K |
Performance Analysis
BULLISHGRI shows predominantly bullish signals based on its fundamentals and technicals.
Recent News
Last updated: Jul 02, 2026 13:12 UTC
Back to Screener Export Report